J&J CEO projects cancer elimination within a decade through immunotherapy breakthroughs

At the WSJ Leadership Institute summit, Johnson & Johnson CEO Joaquin Duato said the company aims to eliminate cancer within 10 years, citing breakthroughs in immunotherapy that have extended remission in multiple myeloma and improved longevity, with AI and biomarkers enabling earlier diagnosis and more personalized treatments. He suggested some cancers could be cured while others become chronic, and noted J&J's acquisitions like Firefly Bio to target difficult mutations, alongside advances such as a melanoma vaccine study by Merck and Moderna that underscores rapid progress in oncology.